Fundraising momentum RiverVest has grown its AUM to approximately $750 million and completed multiple notable fundraises, signaling ongoing capacity for late-stage investments and potential participation in co-led rounds or fund-level partnerships.

Life science focus As a dedicated life science venture partner with a portfolio spanning biopharma and medical devices, RiverVest seeks scientifically rigorous startups and ventures complementary to patient outcomes, presenting opportunities for early discovery-stage collaborations and joint ventures.

Strategic exits Recent exits and board-level involvement at portfolio companies indicate a preference for strategic partnerships and potential acquisition or licensing conversations that could align with our product pipelines or platform technologies.

Geographic reach With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest maintains a national footprint that can align with regional clinical networks, academic partnerships, and access to diverse innovation ecosystems for deal sourcing.

Recent activity Active investments in Wugen and historical stakes in Alleviant Medical, Biolinq, Sparrow Pharma, and others demonstrate ongoing scouting for breakthrough modalities and devices, suggesting receptivity to compelling clinical-stage heat with differentiated tech.